Published in Lancet on October 16, 2010
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Personalized medicine: hope or hype? Eur Heart J (2012) 1.80
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov (2013) 1.78
Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol (2012) 1.44
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics (2013) 1.19
Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol (2011) 1.12
Genetic susceptibility to ischemic stroke. Nat Rev Neurol (2011) 1.12
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J (2012) 0.97
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One (2012) 0.91
Genetics of platelet inhibitor treatment. Br J Clin Pharmacol (2014) 0.89
Clopidogrel and proton pump inhibitors--where do we stand in 2012? World J Gastroenterol (2012) 0.85
Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol (2010) 0.85
Critical appraisal of ticagrelor in the management of acute coronary syndrome. Ther Clin Risk Manag (2011) 0.85
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej (2015) 0.84
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol (2012) 0.84
The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol (2011) 0.84
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J (2011) 0.84
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics. PLoS Curr (2010) 0.84
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J (2012) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet (2013) 0.83
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med (2012) 0.83
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One (2014) 0.82
The genetics of common variation affecting platelet development, function and pharmaceutical targeting. J Thromb Haemost (2011) 0.82
Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther (2011) 0.81
P2Y12-ADP receptor antagonists: Days of future and past. World J Cardiol (2016) 0.80
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clin Transl Sci (2016) 0.80
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Ther Adv Chronic Dis (2015) 0.80
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Br J Clin Pharmacol (2012) 0.80
DMET™ (Drug Metabolism Enzymes and Transporters): a Pharmacogenomic platform for precision medicine. Oncotarget (2016) 0.80
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol (2015) 0.79
Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep (2013) 0.79
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? Cardiol Res Pract (2013) 0.79
Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Circ Cardiovasc Genet (2014) 0.79
Application of personalized medicine to chronic disease: a feasibility assessment. Clin Transl Med (2013) 0.79
Personalized vascular medicine: individualizing drug therapy. Vasc Med (2011) 0.79
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care. BMC Cardiovasc Disord (2013) 0.79
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol (2012) 0.79
Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. Diabetes Care (2012) 0.78
Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol (2010) 0.78
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiol Res Pract (2017) 0.78
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. J Atheroscler Thromb (2016) 0.77
Response to antiplatelet treatment: from genes to outcome. Lancet (2010) 0.77
TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc Ther (2011) 0.77
Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet (2015) 0.77
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J (2015) 0.77
Pharmacogenomic testing and antithrombotic therapy: ready for prime time? Rambam Maimonides Med J (2013) 0.77
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wien Klin Wochenschr (2011) 0.77
Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia. Br J Cancer (2014) 0.76
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. Exp Ther Med (2014) 0.76
Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol (2013) 0.76
The intelligent use and clinical benefits of electronic medical records in multiple sclerosis. Expert Rev Clin Immunol (2014) 0.76
Clopidogrel resistance - a clear problem with an unclear solution. Indian Heart J (2012) 0.75
Cardiovascular drugs and the genetic response. Methodist Debakey Cardiovasc J (2014) 0.75
Pharmacogenetics: Clinical response to antiplatelet therapy--how much does genotype count? Nat Rev Cardiol (2010) 0.75
ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel. Meta Gene (2014) 0.75
Oral antiplatelet therapy in acute coronary syndromes: recent developments. Cardiol Ther (2013) 0.75
Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome. Drug Metab Lett (2016) 0.75
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. Interv Cardiol Clin (2017) 0.75
Routine genotyping of patients on clopidogrel: Why the resistance? Indian Heart J (2015) 0.75
Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting. Genomics (2013) 0.75
Is ticagrelor the antiplatelet therapy panacea? Circ Cardiovasc Genet (2010) 0.75
Gene-drug interaction in stroke. Stroke Res Treat (2011) 0.75
Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention. Front Pharmacol (2016) 0.75
Oral antiplatelet therapy in acute coronary syndromes: update 2012. Eur Heart J Acute Cardiovasc Care (2012) 0.75
Multidrug resistance 1 gene variants, pesticide exposure, and increased risk of DNA damage. Biomed Res Int (2014) 0.75
The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent. Data Brief (2016) 0.75
Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel. Int J Mol Sci (2014) 0.75
Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. J Zhejiang Univ Sci B (2017) 0.75
Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Eur J Clin Pharmacol (2017) 0.75
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. Eur J Clin Pharmacol (2017) 0.75
The Potential of Pharmacogenomics to Advance Kidney Disease Treatment. Clin J Am Soc Nephrol (2017) 0.75
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther (2017) 0.75
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 3.92
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 3.49
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost (2007) 3.38
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol (2008) 3.10
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol (2006) 2.33
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J (2009) 1.92
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv (2008) 1.63
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol (2009) 1.57
Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther (2006) 1.57
Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost (2007) 1.45
Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther (2002) 1.30
Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics (2007) 1.30
Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab (2008) 1.29
Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull (2002) 1.23
Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2007) 1.16
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Universal definition of myocardial infarction. Circulation (2007) 11.69
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Rapid whole-genome mutational profiling using next-generation sequencing technologies. Genome Res (2008) 8.01
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation (2004) 6.34
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med (2011) 5.16
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med (2005) 4.13
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09